Journal article
Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program
Abstract
OBJECTIVE: The objective of this study was to evaluate persistence with denosumab among postmenopausal women with osteoporosis participating in the Canadian patient-support program (ProVital * ). Denosumab is an injectable therapeutic option for osteoporosis that is administered subcutaneously every 6 months.
METHODS: ProVital, a support program in which patients voluntarily enroll, provides next injection reminder calls and educational …
Authors
Papaioannou A; Khan A; Belanger A; Bensen W; Kendler D; Theoret F; Amin M; Brekke L; Erdmann M; Walker V
Journal
Current Medical Research and Opinion, Vol. 31, No. 7, pp. 1391–1401
Publisher
Taylor & Francis
Publication Date
July 3, 2015
DOI
10.1185/03007995.2015.1053049
ISSN
0300-7995